Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00976261 | A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes | PHASE1 | COMPLETED | 72 | — | — | Oct 17, 2009 | Sep 5, 2010 | Jun 8, 2017 | 9 | United States, France +2 |
| Arm | Type | Description |
|---|---|---|
| GSK1614235 | EXPERIMENTAL | Glucose lowering agent under investigation. |
| Sitagliptin | ACTIVE_COMPARATOR | Glucose lowering comparator |
| Placebo | PLACEBO_COMPARATOR | Placebo to match GSK1614235 and placebo to match Sitagliptin |
| Name | Type | Description |
|---|---|---|
| GSK1614235 | DRUG | Glucose lowering in Type 2 Diabetes Mellitus |
| Sitagliptin | DRUG | Glucose lowering in Type 2 Diabetes Mellitus |
| Placebo | OTHER | Comparator |
Inclusion Criteria Part A: * Subjects with documented type 2 diabetes mellitus diagnosis whose HbA1c levels are \>7 and at or less than 9.5%; at screening, who are either controlled by diet alone, or are on monotherapy with oral sulfonylureas, DPP-IV inhibitors (e.g. sitagliptin), or metformin. * M...